June 10, 2003

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

Structured PICO

Does infliximab improve the clinical condition in patients with moderate-to-severe chronic heart failure?

Population

Patients with moderate-to-severe chronic heart failure

Intervention

Infliximab (short-term TNFalpha antagonism, including high doses of 10 mg/kg)

Comparator

Placebo

Outcome

Clinical condition

Short-term use of infliximab does not benefit and may harm patients with moderate-to-severe heart failure, particularly at high doses.

Abstract

Short-term TNFalpha antagonism with infliximab did not improve and high doses (10 mg/kg) adversely affected the clinical condition of patients with moderate-to-severe chronic heart failure.

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

Structured PICO

Abstract

Cite This Study

Also Consider

Also Consider